Registration
  • Traders Union
  • All News
  • Biotech Research, Rare Disease Therapies, and Clinical Trials by Edgewise Therapeutics
Advertiser Disclosure

Biotech Research, Rare Disease Therapies, and Clinical Trials by Edgewise Therapeutics

Edgewise Therapeutics stock consolidates near key support as bullish momentum persists
  • Andreas Kristo
  • 03.07.2026
Edgewise Therapeutics stock consolidates near key support as bullish momentum persists
Edgewise Therapeutics announced that its team is attending the International Congress on Neuromuscular Diseases in Florence, Italy.The company said it looks forward to connecting with leaders in ...
Edgewise Therapeutics stock surges 8.94% to $42.30 as company gears up for EAN poster reveal
  • Andreas Kristo
  • 25.06.2026
Edgewise Therapeutics stock surges 8.94% to $42.30 as company gears up for EAN poster reveal
Edgewise Therapeutics will present the rationale, study design and baseline characteristics of its GRAND CANYON pivotal cohort at the 12th Congress of the European Academy of Neurology.The data ...
Edgewise Therapeutics stock jumps 5.89 percent as company readies for BIO 2026 event
  • Emilio Ghigini
  • 24.06.2026
Edgewise Therapeutics stock jumps 5.89 percent as company readies for BIO 2026 event
Edgewise Therapeutics will participate in the 2026 BIO International Convention. The stock draws attention as its VP of Patient Advocacy, Abby Bronson, will speak at the event.Bronson will address ...
Edgewise Therapeutics team to attend 2026 American College of Cardiology annual meeting
  • Andreas Kristo
  • 20.03.2026
Edgewise Therapeutics team to attend 2026 American College of Cardiology annual meeting
Edgewise Therapeutics announced it will participate in the 2026 American College of Cardiology Annual Scientific Sessions. The company aims to engage with healthcare professionals, academics, ...
Edgewise Therapeutics CEO to outline 2026 goals at JPMorgan event
  • Dmytro Kharkov
  • 06.01.2026
Edgewise Therapeutics CEO to outline 2026 goals at JPMorgan event
Edgewise Therapeutics is set to present its strategic goals at the 44th Annual JPMorgan Healthcare Conference. Kevin Koch, Ph.D., CEO of Edgewise Therapeutics, will discuss the company's ...
Edgewise Therapeutics prepares for pivotal research in cardiovascular medicine
  • Hlib Chabaniuk
  • 03.11.2025
Edgewise Therapeutics prepares for pivotal research in cardiovascular medicine
Edgewise Therapeutics announced its active participation in upcoming major scientific events focused on cardiovascular medicine. Representatives from the company will be attending the Hypertrophic ...
Edgewise Therapeutics set to unveil Q3 2025 results pre-market Nov 6
  • Artem Shendetskii
  • 30.10.2025
Edgewise Therapeutics set to unveil Q3 2025 results pre-market Nov 6
Edgewise Therapeutics has announced plans to release its Q3 2025 financial results on November 6, before the market opens. The upcoming report will provide insights into the company's recent ...
Edgewise Therapeutics publishes data on major Becker Muscular Dystrophy trial
  • Dmytro Kharkov
  • 27.10.2025
Edgewise Therapeutics publishes data on major Becker Muscular Dystrophy trial
Edgewise Therapeutics has announced the publication of findings from its groundbreaking trial, CANYON, addressing Becker Muscular Dystrophy. This is the largest interventional study conducted to ...
Edgewise Therapeutics sponsors major cardiovascular genomics conference
  • Parshwa Turakhiya
  • 25.10.2025
Edgewise Therapeutics sponsors major cardiovascular genomics conference
Edgewise Therapeutics will take part in the 10th International Cardiovascular Genomic Medicine & SickKids Cardiac Precision Medicine Conference in Toronto. The company acts as a sponsor for this ...
Edgewise Therapeutics presents muscular dystrophy research at Vienna conference
  • Anastasiia Chabaniuk
  • 06.10.2025
Edgewise Therapeutics presents muscular dystrophy research at Vienna conference
Edgewise Therapeutics is showcasing its muscular dystrophy research at the World Muscle Society conference in Vienna. The company will present scientific poster displays during session 4 on ...
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org World Association of News Publishers https://gdpr.eu/ GDPR